TP53 and colorectal carcinoma: This recruitment inhibits HNRNPB2A1’s binding to the m6A-modified p53 pre-mRNA, diminishing p53’s inhibitory effect on PHGDH expression, promoting serine-glycine metabolism and redox homeostasis, and ultimately facilitating CRC progression [122].